Endocrinology Peer Insight Report
Endocrinologist perspectives on how incretin therapy is moving from initiation to long-term management, where access, tolerability, plateaus, muscle preservation, and maintenance strategy become the harder questions.
Audience:
Countries: 6
Survey records:
-Hero findings
– Quick Read — Key Findings
Explore the full pattern across access, tolerability, treatment plateaus, muscle preservation, maintenance dosing, and emerging therapies.
GLP-1 receptor agonists and dual GIP/GLP-1 therapies now sit at the center of diabetes and obesity care for many endocrinologists. The clinical conversation has expanded accordingly. Once treatment begins, the questions move quickly from efficacy to persistence: Can the patient afford to stay on therapy? How are side effects managed without losing benefit? What happens when weight plateaus while glycemia remains stable? And what does maintenance look like after a goal is reached?
The 2026 American Diabetes Association Standards describe GLP-1 based therapy as central to weight and glycemic management for many people with type 2 diabetes and obesity, while also emphasizing individualized titration, nutrition, and the chronic nature of pharmacotherapy. That broader context makes the survey pattern important: endocrinologists are not describing a single medication choice. They are describing an expanding management workload around successful long-term use.
The responses suggest that the main friction is shifting downstream. High prescribing exposure sits alongside affordability problems, gastrointestinal tolerability, uncertainty about maintenance dosing, and uneven monitoring of lean mass. The emerging picture is one of therapeutic confidence paired with practical complexity.
Clinical context: American Diabetes Association, Standards of Care in Diabetes 2026 – Obesity and Weight Management; American Diabetes Association, Standards of Care in Diabetes 2026 – Pharmacologic Approaches
The survey includes professionals from United States, United Kingdom, Canada, Italy, France, Germany.
MDForLives Research Interpretation
More than nine in ten respondents report that at least one-quarter of their weekly T2D or obesity caseload is receiving an incretin-based therapy, and 41.9% place that share above one-half.
What the pattern suggests: These therapies are no longer an occasional specialist option in this cohort. They are embedded deeply enough in routine caseloads that downstream management issues become everyday endocrinology work.
What may be behind it: Broader indications, strong glycemic and weight effects, and expanding cardiometabolic evidence have increased exposure, while the chronic nature of therapy keeps patients in ongoing follow-up.
Why it matters: When a therapy becomes this common, access, tolerability, body composition, and maintenance strategy become service-level issues rather than isolated patient exceptions.
Financial barriers are named by 54.8% as the most common reason patients temporarily or permanently discontinue treatment, ahead of gastrointestinal side effects at 32.3%.
What the pattern suggests: The strongest break in persistence is not described as lack of efficacy. It is whether treatment remains economically reachable over time.
What may be behind it: Coverage denials, copays, and formulary restrictions can interrupt therapy even when the clinical response is acceptable, turning treatment continuity into an access problem.
Why it matters: The data separates therapeutic effectiveness from treatment sustainability. A drug can work clinically and still fail as a long-term plan when the financing of care is unstable.
When gastrointestinal side effects become a problem, 83.8% either slow titration substantially or switch to another molecule within the incretin class.
What the pattern suggests: The class itself retains clinical value in the eyes of most respondents even when the first treatment experience is difficult.
What may be behind it: Tolerability can vary with dose escalation, molecule, eating patterns, and individual gastrointestinal sensitivity, leaving room to modify the pathway without giving up the mechanism entirely.
Why it matters: The pattern frames adverse effects as a management problem to work around, while also showing how much additional follow-up can sit behind a seemingly simple medication change.
Just over half wait 3 to 6 months before changing the pharmacological regimen after a plateau, while 16.7% rarely switch if glycemic control remains stable.
What the pattern suggests: Weight and glycemic goals are not being treated as interchangeable endpoints. Stable HbA1c can justify a different response to a weight plateau than a broader loss of treatment benefit.
What may be behind it: Plateaus may reflect biology, adherence, nutrition, dose tolerance, or a new steady state, so many clinicians appear to allow time for the pattern to declare itself before changing treatment.
Why it matters: The finding shows why long-term incretin management becomes multidimensional: the decision depends on which outcome has plateaued and which outcomes remain protected.
High-protein nutrition and structured resistance training lead the response at 53.3%, while one-third report no routine screening unless frailty is evident.
What the pattern suggests: The survey shows stronger consensus around prevention behaviors than around objective measurement of body composition.
What may be behind it: DXA or bioimpedance testing may not be built into every endocrine workflow, whereas nutrition and exercise counseling are more immediately available.
Why it matters: The gap is not necessarily a lack of concern. It may reflect the practical distance between recognizing lean-mass risk and having scalable tools to quantify it routinely.
Half favor a lower maintenance dose after goals are reached, while only 10.0% prefer complete discontinuation and transition away from incretin therapy.
What the pattern suggests: Most respondents appear to view success as something that still requires pharmacologic maintenance, even when intensity may change.
What may be behind it: Concerns about weight recurrence and cardiometabolic deterioration after stopping therapy make complete withdrawal a less common default, while lower-dose maintenance offers a middle path.
Why it matters: The survey points to an emerging long-term question for endocrinology: not simply when to stop, but how to define the least burdensome regimen that preserves benefit.
High exposure to incretin therapy means the workload increasingly sits in maintenance decisions, not only initiation. The opinions point to a longer care arc involving access, tolerance, plateaus, muscle preservation, and dose strategy.
Financial barriers lead the discontinuation pattern by a wide margin. This suggests that insurance and out-of-pocket cost can shape persistence as directly as biological response in routine practice.
Most respondents address lean-mass risk through nutrition and resistance training, but objective body-composition monitoring is uncommon. The hidden tension may be less about awareness and more about what the clinic can measure efficiently.
The survey portrays endocrinologists as broadly committed to incretin therapy, but increasingly occupied by the work required to keep it viable over time. Financial access is the clearest disruption, while tolerability, weight plateaus, muscle preservation, and maintenance dosing create additional layers of decision-making.
The most interesting pattern is that clinicians rarely respond to difficulty by abandoning the mechanism immediately. They slow titration, switch within class, wait through plateaus, and often maintain treatment after goals are reached. That suggests a field moving from an initiation mindset toward chronic therapeutic stewardship.
You have read the summary
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
